Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Deffered Revenue: 2010-2025

Historic Non-Current Deffered Revenue for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Sep 2025 value amounting to $12.5 million.

  • Lineage Cell Therapeutics' Non-Current Deffered Revenue fell 22.36% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 22.36%. This contributed to the annual value of $14.4 million for FY2024, which is 22.79% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Non-Current Deffered Revenue is $12.5 million, which was down 2.27% from $12.8 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Non-Current Deffered Revenue high stood at $32.5 million for Q4 2021, and its period low was $12.5 million during Q3 2025.
  • For the 3-year period, Lineage Cell Therapeutics' Non-Current Deffered Revenue averaged around $17.4 million, with its median value being $18.2 million (2024).
  • Data for Lineage Cell Therapeutics' Non-Current Deffered Revenue shows a maximum YoY plummeted of 32.58% (in 2023) over the last 5 years.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $32.5 million in 2021, then decreased by 14.57% to $27.7 million in 2022, then plummeted by 32.58% to $18.7 million in 2023, then decreased by 22.79% to $14.4 million in 2024, then declined by 22.36% to $12.5 million in 2025.
  • Its Non-Current Deffered Revenue was $12.5 million in Q3 2025, compared to $12.8 million in Q2 2025 and $13.6 million in Q1 2025.